Nerve Growth Factor Market : Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6900
$ 8900

Nerve growth factor (NGF) is a neurotrophic factor and neuropeptide primarily involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. NGF plays a pivotal role in the modulation of nociception in adulthood. There are 2 receptors for NGF, p75 neurotrophins receptor (p75NTR) and tropomyosin receptor kinase A (TrkA).  The mechanism of action (MOA) of the NGF is the NGF binds to TrkA with high specificity, initiating the signaling cascade. This interaction occurs when NGF binds to the extracellular domain of TrkA. Binding induces dimerization of TrkA receptors, bringing two receptor molecules close together. This dimerization activates the intracellular kinase domain of TrkA, leading to the autophosphorylation of specific tyrosine residues within the receptors. The autophosphorylation of TrkA receptors creates docking sites for intracellular signaling proteins, which in turn activate several downstream signaling pathways. One of the primary pathways activated by NGF is the mitogen-activated protein kinase (MAPK) pathway. This pathway promotes cell growth and differentiation by regulating gene expression. NGF is used in the treatment of arthritis, joint disorder, neuromuscular diseases, endocrine system diseases, diabetes mellitus, eye diseases, urologic diseases, etc. Increased prevalence of osteoarthritis and joint disorders and increased R&D investment are the key drivers for the Nerve Growth Factor market. For instance, according to the Centers for Disease Control and Prevention 2020, around there were 32.5 million US adults diagnosed with osteoarthritis. The introduction of newer products by market players may look for opportunities that have a big impact on comprehensive research and development in Nerve Growth Factor antagonists. For instance, Pfizer submitted BLA (biologic licensed application) for Tanezumab, and will be launched in the forthcoming period.

Nerve Growth Factor Market Key Developments:

In March 2022, Pfizer in global collaboration with Eli Lilly’s biologic product Tanezumab’s and Biologics License Application (BLA) were accepted by FDA  for a potential first-in-class treatment for patients with chronic pain caused by moderate-to-severe osteoarthritis.

Approved Drug Molecules and Brand Names for Nerve Growth Factor:

  • Oxervate (Cenegermin-bkbj)

Drugs under the Pipeline for Nerve Growth Factor:

  • Raylumis (Tanezumab)
  • Sentinel (Cenegermin-Bkbj)
  • Fasinumab (REGN475)
  • Fulranumab (AMG-403)
  • Neublastin (ARTN)
  • MEDI7352
  • Liatermin (R-Methugdnf)
  • Cogane (Sarsasapogenin)
  • PG-110
  • SB623
  • Mercaptopurine Delayed Release (DR6MP)
  • ASP6294
  • CERE-110
  • LEVI 04
  • LM11A-31-BHS
  • NB-01
  • Tulrampator (S47445)
  • CXCR2 And NGFR Transduced TIL
  • DE-105
  • EP-9001A
  • Engedi 1000
  • KP544
  • MEDI-578
  • NNI-362
  • TAC-302

Clinical Activity and Developments of Nerve Growth Factor:

  • As of July 2023, there will be about 22 companies with over 34 compounds that focus on various forms of arthritis and neuropathic pain. For these molecules, more than 130 clinical trials are being conducted and the majority are in phase-2 and phase-3 clinical trials. For instance,
  • In April 2022, Dompe Pharmaceutical completed phase 4, a multicenter, open label, prospective study with 24 weeks of follow-up to evaluate safety and efficacy of Oxervate 0.002% (20 mcg/mL) and Cenegermin-bkbj ophthalmic solution in patients with stage 1 neurotrophic keratitis (nk).
  • In April 2023, Pfizer in global collaboration with Eli Lilly completed phase 3, a randomized, double-blind, placebo-controlled, multicenter study to evaluate the analgesic efficacy and safety of the subcutaneous administration of Tanezumab in subjects with osteoarthritis of the hip or knee.

Molecule Name

Number of Studies

Raylumis (Tanezumab)


Sentinel (Cenegermin-Bkbj)


Fasinumab (REGN475)


Fulranumab (AMG-403)


Neublastin (ARTN)



Nerve Growth Factor Market Dynamics

The molecules such as Oxervate (Cenegermin-bkbj) is a recombinant human nerve growth factor developed by Dompe Pharmaceutical for the line of treatment specifically indicated for the treatment of neurotrophic keratitis as topical ophthalmologic administration. Moreover, Eli Lilly in collaboration with Pfizer Tanezumab is a nerve growth factor (NGF) inhibitor in development for the treatment of patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics.

Frequently Asked Questions

Oxervate (Cenegermin-bkbj) is the only FDA approved Nerve Growth Factor.

Eli Lilly, Pfizer, and Dompe are a few leading market players in Nerve Growth Factor Market.

Arthritis, joint disorder, neuromuscular diseases, endocrine system diseases, diabetes mellitus, eye diseases, urologic diseases, etc are the major indication of Nerve Growth Factor.

There are a total of 25 molecules that are in the Phase-1, Phase-2, and Phase-3 clinical development.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Eli Lilly
  • Pfizer
  • Dompe
  • Teva
  • Amgen
  • Biogen
  • AstraZeneca
  • MedGenesis
  • AbbVie
  • SanBio
  • Astellas
  • Levicept
  • PharmatrophiX
  • NeuroBo
  • Servier
  • Santen
  • Easton Biopharma
  • Ensol Biosci
  • CeNeRx
  • NeuroNascent

Adjacent Markets